These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 27551071)

  • 21. A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients.
    Suzuki E; Niwa R; Saji S; Muta M; Hirose M; Iida S; Shiotsu Y; Satoh M; Shitara K; Kondo M; Toi M
    Clin Cancer Res; 2007 Mar; 13(6):1875-82. PubMed ID: 17363544
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion.
    Hudak JE; Canham SM; Bertozzi CR
    Nat Chem Biol; 2014 Jan; 10(1):69-75. PubMed ID: 24292068
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trogocytosis-mediated expression of HER2 on immune cells may be associated with a pathological complete response to trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patients.
    Suzuki E; Kataoka TR; Hirata M; Kawaguchi K; Nishie M; Haga H; Toi M
    BMC Cancer; 2015 Feb; 15():39. PubMed ID: 25655677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PDPN positive CAFs contribute to HER2 positive breast cancer resistance to trastuzumab by inhibiting antibody-dependent NK cell-mediated cytotoxicity.
    Du R; Zhang X; Lu X; Ma X; Guo X; Shi C; Ren X; Ma X; He Y; Gao Y; Liu Y
    Drug Resist Updat; 2023 May; 68():100947. PubMed ID: 36812747
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines.
    Collins DM; Gately K; Hughes C; Edwards C; Davies A; Madden SF; O'Byrne KJ; O'Donovan N; Crown J
    Cell Immunol; 2017 Sep; 319():35-42. PubMed ID: 28735814
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive Cancers.
    Lee SC; Shimasaki N; Lim JSJ; Wong A; Yadav K; Yong WP; Tan LK; Koh LP; Poon MLM; Tan SH; Ow SGW; Bharwani L; Yap YS; Foo MZQ; Coustan-Smith E; Sundar R; Tan HL; Chong WQ; Kumarakulasinghe NB; Lieow JLM; Koe PJX; Goh BC; Campana D
    Clin Cancer Res; 2020 Sep; 26(17):4494-4502. PubMed ID: 32522887
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR.
    Roberti MP; Barrio MM; Bravo AI; Rocca YS; Arriaga JM; Bianchini M; Mordoh J; Levy EM
    Breast Cancer Res Treat; 2011 Nov; 130(2):465-75. PubMed ID: 21308409
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of NKG2D ligands and subsequent enhancement of NK cell-mediated lysis of cancer cells by arsenic trioxide.
    Kim JY; Bae JH; Lee SH; Lee EY; Chung BS; Kim SH; Kang CD
    J Immunother; 2008 Jun; 31(5):475-86. PubMed ID: 18463537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanisms of escape from trastuzumab-mediated ADCC in esophageal squamous cell carcinoma: relation to susceptibility to perforin-granzyme.
    Kawaguchi Y; Kono K; Mizukami Y; Mimura K; Fujii H
    Anticancer Res; 2009 Jun; 29(6):2137-46. PubMed ID: 19528474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting ADCC: A different approach to HER2 breast cancer in the immunotherapy era.
    Mandó P; Rivero SG; Rizzo MM; Pinkasz M; Levy EM
    Breast; 2021 Dec; 60():15-25. PubMed ID: 34454323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab.
    Tokuyama H; Hagi T; Mattarollo SR; Morley J; Wang Q; So HF; Moriyasu F; Nieda M; Nicol AJ
    Int J Cancer; 2008 Jun; 122(11):2526-34. PubMed ID: 18307255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Focusing on NK cells and ADCC: A promising immunotherapy approach in targeted therapy for HER2-positive breast cancer.
    Li F; Liu S
    Front Immunol; 2022; 13():1083462. PubMed ID: 36601109
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy.
    Muraro E; Comaro E; Talamini R; Turchet E; Miolo G; Scalone S; Militello L; Lombardi D; Spazzapan S; Perin T; Massarut S; Crivellari D; Dolcetti R; Martorelli D
    J Transl Med; 2015 Jun; 13():204. PubMed ID: 26116238
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cancer immunotherapy using NKG2D and DNAM-1 systems.
    Morisaki T; Onishi H; Katano M
    Anticancer Res; 2012 Jun; 32(6):2241-7. PubMed ID: 22641658
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor immunity. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection.
    Deng W; Gowen BG; Zhang L; Wang L; Lau S; Iannello A; Xu J; Rovis TL; Xiong N; Raulet DH
    Science; 2015 Apr; 348(6230):136-9. PubMed ID: 25745066
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC.
    Inagaki A; Ishida T; Yano H; Ishii T; Kusumoto S; Ito A; Ri M; Mori F; Ding J; Komatsu H; Iida S; Ueda R
    Int J Cancer; 2009 Jul; 125(1):212-21. PubMed ID: 19358282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody-dependent cell cytotoxicity to breast cancer targets despite inhibitory KIR signaling.
    Stein MN; Shin J; Gudzowaty O; Bernstein AM; Liu JM
    Anticancer Res; 2006; 26(3A):1759-63. PubMed ID: 16827104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition.
    Mamessier E; Sylvain A; Bertucci F; Castellano R; Finetti P; Houvenaeghel G; Charaffe-Jaufret E; Birnbaum D; Moretta A; Olive D
    Cancer Res; 2011 Nov; 71(21):6621-32. PubMed ID: 21937679
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
    Sliwkowski MX; Lofgren JA; Lewis GD; Hotaling TE; Fendly BM; Fox JA
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):60-70. PubMed ID: 10482195
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Susceptibility of CD24(+) ovarian cancer cells to anti-cancer drugs and natural killer cells.
    Koh J; Lee SB; Park H; Lee HJ; Cho NH; Kim J
    Biochem Biophys Res Commun; 2012 Oct; 427(2):373-8. PubMed ID: 22995296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.